Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 441

1.

Role of Physician-Scientists in the Control of Human Immunodeficiency Virus.

Merigan TC.

J Infect Dis. 2018 Aug 14;218(suppl_1):S3-S6. doi: 10.1093/infdis/jiy089.

PMID:
30124973
2.

In vitro HIV-1 evolution in response to triple reverse transcriptase inhibitors & in silico phenotypic analysis.

Rath BA, Yousef KP, Katzenstein DK, Shafer RW, Schütte C, von Kleist M, Merigan TC.

PLoS One. 2013 Apr 17;8(4):e61102. doi: 10.1371/journal.pone.0061102. Print 2013.

3.

Persistence versus reversion of 3TC resistance in HIV-1 determine the rate of emergence of NVP resistance.

Rath BA, Olshen RA, Halpern J, Merigan TC.

Viruses. 2012 Aug;4(8):1212-34. doi: 10.3390/v4081212. Epub 2012 Aug 7.

4.

Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells.

Mitsuyasu RT, Merigan TC, Carr A, Zack JA, Winters MA, Workman C, Bloch M, Lalezari J, Becker S, Thornton L, Akil B, Khanlou H, Finlayson R, McFarlane R, Smith DE, Garsia R, Ma D, Law M, Murray JM, von Kalle C, Ely JA, Patino SM, Knop AE, Wong P, Todd AV, Haughton M, Fuery C, Macpherson JL, Symonds GP, Evans LA, Pond SM, Cooper DA.

Nat Med. 2009 Mar;15(3):285-92. doi: 10.1038/nm.1932. Epub 2009 Feb 15.

5.

Multilocus genetic interactions and response to efavirenz-containing regimens: an adult AIDS clinical trials group study.

Motsinger AA, Ritchie MD, Shafer RW, Robbins GK, Morse GD, Labbe L, Wilkinson GR, Clifford DB, D'Aquila RT, Johnson VA, Pollard RB, Merigan TC, Hirsch MS, Donahue JP, Kim RB, Haas DW.

Pharmacogenet Genomics. 2006 Nov;16(11):837-45.

PMID:
17047492
6.

Effect of baseline- and treatment-related factors on immunologic recovery after initiation of antiretroviral therapy in HIV-1-positive subjects: results from ACTG 384.

Gandhi RT, Spritzler J, Chan E, Asmuth DM, Rodriguez B, Merigan TC, Hirsch MS, Shafer RW, Robbins GK, Pollard RB; ACTG 384 Team.

J Acquir Immune Defic Syndr. 2006 Aug 1;42(4):426-34.

PMID:
16810109
7.

"Wide-open" 1.3 A structure of a multidrug-resistant HIV-1 protease as a drug target.

Martin P, Vickrey JF, Proteasa G, Jimenez YL, Wawrzak Z, Winters MA, Merigan TC, Kovari LC.

Structure. 2005 Dec;13(12):1887-95.

8.

Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study.

Haas DW, Smeaton LM, Shafer RW, Robbins GK, Morse GD, Labbe L, Wilkinson GR, Clifford DB, D'Aquila RT, De Gruttola V, Pollard RB, Merigan TC, Hirsch MS, George AL Jr, Donahue JP, Kim RB.

J Infect Dis. 2005 Dec 1;192(11):1931-42. Epub 2005 Nov 1.

PMID:
16267764
9.

Pharmacokinetics of nelfinavir and efavirenz in antiretroviral-naive, human immunodeficiency virus-infected subjects when administered alone or in combination with nucleoside analog reverse transcriptase inhibitors.

Smith PF, Robbins GK, Shafer RW, Wu H, Yu S, Hirsch MS, Merigan TC, Park JG, Forrest A, Fischl MA, Morse GD; ACTG 384-5006 Team.

Antimicrob Agents Chemother. 2005 Aug;49(8):3558-61.

10.

Antiviral activity of lamivudine in salvage therapy for multidrug-resistant HIV-1 infection.

Campbell TB, Shulman NS, Johnson SC, Zolopa AR, Young RK, Bushman L, Fletcher CV, Lanier ER, Merigan TC, Kuritzkes DR.

Clin Infect Dis. 2005 Jul 15;41(2):236-42. Epub 2005 Jun 7.

PMID:
15983922
11.

Insertions in the human immunodeficiency virus type 1 protease and reverse transcriptase genes: clinical impact and molecular mechanisms.

Winters MA, Merigan TC.

Antimicrob Agents Chemother. 2005 Jul;49(7):2575-82. Review. No abstract available.

12.

New two-amino acid insertion near codon 70 of the HIV type 1 protease gene.

Winters MA, Kagan RM, Heseltine PN, Merigan TC.

AIDS Res Hum Retroviruses. 2005 Apr;21(4):311-3.

PMID:
15943574
13.
14.

Nonnucleoside reverse transcriptase inhibitor phenotypic hypersusceptibility can be demonstrated in different assays.

Shulman NS, Delgado J, Bosch RJ, Winters MA, Johnston E, Shafer RW, Katzenstein DA, Merigan TC.

J Acquir Immune Defic Syndr. 2005 May 1;39(1):78-81.

PMID:
15851917
15.

Human immunodeficiency virus type 1 infection in Oman: antiretroviral therapy and frequencies of drug resistance mutations.

Al Dhahry SH, Scrimgeour EM, Al Suwaid AR, Al Lawati MR, El Khatim HS, Al Kobaisi MF, Merigan TC.

AIDS Res Hum Retroviruses. 2004 Nov;20(11):1166-72.

PMID:
15588338
16.

Association of a novel human immunodeficiency virus type 1 protease substrate cleft mutation, L23I, with protease inhibitor therapy and in vitro drug resistance.

Johnston E, Winters MA, Rhee SY, Merigan TC, Schiffer CA, Shafer RW.

Antimicrob Agents Chemother. 2004 Dec;48(12):4864-8.

17.

Increasing prevalence of HIV-1 reverse transcriptase mutation K65R correlates with tenofovir utilization.

Kagan RM, Merigan TC, Winters MA, Heseltine PN.

Antivir Ther. 2004 Oct;9(5):827-8. No abstract available.

PMID:
15535422
18.

Crystal structures of a multidrug-resistant human immunodeficiency virus type 1 protease reveal an expanded active-site cavity.

Logsdon BC, Vickrey JF, Martin P, Proteasa G, Koepke JI, Terlecky SR, Wawrzak Z, Winters MA, Merigan TC, Kovari LC.

J Virol. 2004 Mar;78(6):3123-32.

19.

Granulocyte-macrophage colony-stimulating factor induces modest increases in plasma human immunodeficiency virus (HIV) type 1 RNA levels and CD4+ lymphocyte counts in patients with uncontrolled HIV infection.

Jacobson JM, Lederman MM, Spritzler J, Valdez H, Tebas P, Skowron G, Wang R, Jackson JB, Fox L, Landay A, Gilbert MJ, O'Neil D, Bancroft L, Al-Harthi L, Jacobson MA, Merigan TC Jr, Glesby MJ; National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.

J Infect Dis. 2003 Dec 15;188(12):1804-14. Epub 2003 Dec 9.

PMID:
14673758
20.

Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection.

Shafer RW, Smeaton LM, Robbins GK, De Gruttola V, Snyder SW, D'Aquila RT, Johnson VA, Morse GD, Nokta MA, Martinez AI, Gripshover BM, Kaul P, Haubrich R, Swingle M, McCarty SD, Vella S, Hirsch MS, Merigan TC; AIDS Clinical Trials Group 384 Team.

N Engl J Med. 2003 Dec 11;349(24):2304-15.

21.

Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection.

Robbins GK, De Gruttola V, Shafer RW, Smeaton LM, Snyder SW, Pettinelli C, Dubé MP, Fischl MA, Pollard RB, Delapenha R, Gedeon L, van der Horst C, Murphy RL, Becker MI, D'Aquila RT, Vella S, Merigan TC, Hirsch MS; AIDS Clinical Trials Group 384 Team.

N Engl J Med. 2003 Dec 11;349(24):2293-303.

22.

Correlation of single photon emission computed tomography parameters as a noninvasive alternative to liver biopsies in assessing liver involvement in the setting of HIV and hepatitis C virus coinfection: a multicenter trial of the Adult AIDS Clinical Trials Group.

Shiramizu B, Theodore D, Bassett R, Coel M, Sherman KE, Glesby MJ, Chow D, Alston B, Colquhoun D, Merigan TC Jr, Reichman RC, Berggren R, Burning WJ, Brobst S; Adult AIDS Clinical Trials Group 5096 Team.

J Acquir Immune Defic Syndr. 2003 Jul 1;33(3):329-35.

PMID:
12843743
23.

HIV-1 protease variants from 100-fold drug resistant clinical isolates: expression, purification, and crystallization.

Vickrey JF, Logsdon BC, Proteasa G, Palmer S, Winters MA, Merigan TC, Kovari LC.

Protein Expr Purif. 2003 Mar;28(1):165-72.

PMID:
12651121
24.

Genotypic and phenotypic analysis of a novel 15-base insertion occurring between codons 69 and 70 of HIV type 1 reverse transcriptase.

Lobato RL, Kim EY, Kagan RM, Merigan TC.

AIDS Res Hum Retroviruses. 2002 Jul 1;18(10):733-6.

PMID:
12167282
25.

Both baseline HIV-1 drug resistance and antiretroviral drug levels are associated with short-term virologic responses to salvage therapy.

Baxter JD, Merigan TC, Wentworth DN, Neaton JD, Hoover ML, Hoetelmans RM, Piscitelli SC, Verbiest WH, Mayers DL; CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS.

AIDS. 2002 May 24;16(8):1131-8.

PMID:
12004271
26.
27.
29.

High degree of interlaboratory reproducibility of human immunodeficiency virus type 1 protease and reverse transcriptase sequencing of plasma samples from heavily treated patients.

Shafer RW, Hertogs K, Zolopa AR, Warford A, Bloor S, Betts BJ, Merigan TC, Harrigan R, Larder BA.

J Clin Microbiol. 2001 Apr;39(4):1522-9.

30.

Anti-HIV type 1 activity of 3'-fluoro-3'-deoxythymidine for several different multidrug-resistant mutants.

Kim EY, Vrang L, Oberg B, Merigan TC.

AIDS Res Hum Retroviruses. 2001 Mar 20;17(5):401-7.

PMID:
11282008
32.

Two double-blinded, randomized, comparative trials of 4 human immunodeficiency virus type 1 (HIV-1) envelope vaccines in HIV-1-infected individuals across a spectrum of disease severity: AIDS Clinical Trials Groups 209 and 214.

Schooley RT, Spino C, Kuritzkes D, Walker BD, Valentine FA, Hirsch MS, Cooney E, Friedland G, Kundu S, Merigan TC Jr, McElrath MJ, Collier A, Plaeger S, Mitsuyasu R, Kahn J, Haslett P, Uherova P, deGruttola V, Chiu S, Zhang B, Jones G, Bell D, Ketter N, Twadell T, Chernoff D, Rosandich M.

J Infect Dis. 2000 Nov;182(5):1357-64. Epub 2000 Oct 9.

PMID:
11023459
33.

Highly active antiretroviral therapy results in HIV type 1 suppression in lymph nodes, increased pools of naive T cells, decreased pools of activated T cells, and diminished frequencies of peripheral activated HIV type 1-specific CD8+ T cells.

Gray CM, Lawrence J, Ranheim EA, Vierra M, Zupancic M, Winters M, Altman J, Montoya J, Zolopa A, Schapiro J, Haase AT, Merigan TC.

AIDS Res Hum Retroviruses. 2000 Sep 20;16(14):1357-69.

PMID:
11018855
34.

In vivo persistence of donor cells following adoptive transfer of allogeneic dendritic cells in HIV-infected patients.

Shapero MH, Kundu SK, Engleman E, Laus R, van Schooten WC, Merigan TC.

Cell Transplant. 2000 May-Jun;9(3):307-17.

PMID:
10972330
35.

A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS.

Baxter JD, Mayers DL, Wentworth DN, Neaton JD, Hoover ML, Winters MA, Mannheimer SB, Thompson MA, Abrams DI, Brizz BJ, Ioannidis JP, Merigan TC.

AIDS. 2000 Jun 16;14(9):F83-93.

PMID:
10894268
36.

Frequency of antiretroviral drug resistance mutations in HIV-1 strains from patients failing triple drug regimens. The Terry Beirn Community Programs for Clinical Research on AIDS.

Winters MA, Baxter JD, Mayers DL, Wentworth DN, Hoover ML, Neaton JD, Merigan TC.

Antivir Ther. 2000 Mar;5(1):57-63.

PMID:
10846594
37.

In Vivo Persistence of Donor Cells following Adoptive Transfer of Allogeneic Dendritic Cells in HIV-Infected Patients.

Shapero MH, Kundu SK, Engleman E, Laus R, Van Schooten WCA, Merigan TC.

Cell Transplant. 2000 May;9(3):307-317. doi: 10.1177/096368970000900302.

PMID:
28880658
38.

Delayed-type hypersensitivity to recombinant HIV envelope glycoprotein (rgp160) after immunization with homologous antigen.

Katzenstein DA, Kundu S, Spritzler J, Smoller BR, Haszlett P, Valentine F, Merigan TC.

J Acquir Immune Defic Syndr. 1999 Dec 1;22(4):341-7.

PMID:
10634195
39.

HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed.

Zolopa AR, Shafer RW, Warford A, Montoya JG, Hsu P, Katzenstein D, Merigan TC, Efron B.

Ann Intern Med. 1999 Dec 7;131(11):813-21.

42.

Impact of prophylactic immediate posttransplant ganciclovir on development of transplant atherosclerosis: a post hoc analysis of a randomized, placebo-controlled study.

Valantine HA, Gao SZ, Menon SG, Renlund DG, Hunt SA, Oyer P, Stinson EB, Brown BW Jr, Merigan TC, Schroeder JS.

Circulation. 1999 Jul 6;100(1):61-6.

PMID:
10393682
43.

Clinical resistance patterns and responses to two sequential protease inhibitor regimens in saquinavir and reverse transcriptase inhibitor-experienced persons.

Lawrence J, Schapiro J, Winters M, Montoya J, Zolopa A, Pesano R, Efron B, Winslow D, Merigan TC.

J Infect Dis. 1999 Jun;179(6):1356-64.

PMID:
10228055
44.

Use of PCR to measure HIV viral changes in drug-resistant genes in genital fluids.

Merigan TC.

J Reprod Immunol. 1998 Dec;41(1-2):177-85.

PMID:
10213309
45.
46.

Frequency of class I HLA-restricted anti-HIV CD8+ T cells in individuals receiving highly active antiretroviral therapy (HAART).

Gray CM, Lawrence J, Schapiro JM, Altman JD, Winters MA, Crompton M, Loi M, Kundu SK, Davis MM, Merigan TC.

J Immunol. 1999 Feb 1;162(3):1780-8.

47.
48.

Role of preimmunization virus sequences in cellular immunity in HIV-infected patients during HIV type 1 MN recombinant gp160 immunization.

Kundu SK, Dupuis M, Sette A, Celis E, Dorner F, Eibl M, Merigan TC.

AIDS Res Hum Retroviruses. 1998 Dec 20;14(18):1669-78.

PMID:
9870321
49.

Resistance mutations to zidovudine and saquinavir in patients receiving zidovudine plus saquinavir or zidovudine and zalcitabine plus saquinavir in AIDS clinical trials group 229.

Schapiro JM, Lawrence J, Speck R, Winters MA, Efron B, Coombs RW, Collier AC, Merigan TC.

J Infect Dis. 1999 Jan;179(1):249-53.

PMID:
9841849
50.

A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors.

Winters MA, Coolley KL, Girard YA, Levee DJ, Hamdan H, Shafer RW, Katzenstein DA, Merigan TC.

J Clin Invest. 1998 Nov 15;102(10):1769-75.

Supplemental Content

Loading ...
Support Center